 |
Phone: 1-800-958-1252
Fax: 1-800-673-9238  |
 |
|
      
Anipryl(Manufactured by: Pfizer Animal Health a Division of Pfizer Australia Pty Ltd)Dose: 15 mgQuantity: 30 tablets Price: $79.95 USD Description of Anipryl Uses Anipryl (selegiline), also known as L-Deprenyl, is a monoamine oxidase inhibitor (MAOI) that treats Cushing's Disease and Canine Cognitive Dysfunction Syndrome (senility).
Dosage and Administration
CDS: The recommended dosage for oral administration for the control of clinical signs associated with CDS is 0.5-1.0 mg/kg once daily, preferably administered in the morning. Initially, dogs should be dosed to the nearest whole tablet. Adjustments should then be made based on response and tolerance to the drug. PDH: The recommended dosage for the control of clinical signs associated with canine PDH is 1.0 mg/kg once daily, preferably administered in the morning. If no improvement is observed after 2 months of therapy, dosage may be increased to a maximum of 2.0 mg/kg once daily. If no improvement is seen after 1 month at the higher dose or if at any time clinical signs progress, the dog should be re-evaluated. In dogs whose clinical signs of PDH progress despite Anipryl therapy in the absence of concurrent disease, alternative therapy should be considered. Dogs should be monitored closely for possible adverse events associated with any increase in dose. Clinical Use of Anipryl in CDS: CDS is an age-related deterioration of cognitive abilities characterized by behavioral changes not wholly attributable to a general medical condition such as neoplasia, infection, or organ failure. CDS is typified by multiple cognitive impairments which affect the dog's function. In clinical trials, the observed behavioral changes associated with CDS in older dogs included: disorientation, decreased activity level, abnormal sleep/wake cycles, loss of housetraining, decreased or altered responsiveness to family members, and decreased or altered greeting behavior. In clinical trials, Anipryl was shown to be effective in controlling clinical signs associated with CDS. After 4 weeks of treatment, dogs treated with Anipryl showed significant improvement when compared to placebo-treated controls in sleeping patterns, housetraining, and activity level. Some dogs showed increased improvement up to 3 months, however, onset, duration and magnitude of response varied with individual dogs. The diagnosis of CDS in dogs is a diagnosis of exclusion, based on thorough behavioral and medical histories, in conjunction with appropriate diagnostic work-up and testing.11 Periodic patient monitoring to evaluate the response and tolerance to the drug and for the presence of concurrent or new disease is recommended. Clinical Use of Anipryl in PDH: Clinical signs of PDH seen in clinical trials included panting, reduced activity, polydipsia, polyuria, changes in sleep patterns, altered appetite, obesity, alopecia, abdominal distention, reduced skin elasticity, thin skin, poor hair growth, pyoderma, decreased responsiveness to attention, and decreased enthusiasm of greeting. In clinical studies involving 125 evaluable cases of naturally occurring PDH, Anipryl was shown to be effective in controlling clinical signs associated with the disease. On physical examination, abdominal distention was the parameter which most consistently improved following treatment with Anipryl. Based on owner assessments, activity level was the parameter most consistently evaluated as “improved”. Approximately 60% of the dogs were evaluated by the veterinarians and owners to be “slightly improved” to “improved” after 1 month of Anipryl therapy. By month 2, veterinarians reported that approximately 77% were “slightly improved” to “improved”. Approximately 20% of dogs did not respond to Anipryl and were deemed treatment failures.
Contra-indications Anipryl is contraindicated in patients with known hypersensitivity to this drug. In humans, selegiline is contraindicated for use with meperidine and this contraindication is often extended to other opioids. WARNINGS: Keep out of reach of children. Not for human use. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). In humans, concurrent use of MAO inhibitors with alpha-2 agonists has resulted in extreme fluctuations of blood pressure; therefore, blood pressure monitoring is recommended with concurrent use in dogs. Also, in humans, severe CNS toxicity including death has been reported with the combination of selegiline and tricyclic antidepressants, and selegiline and selective serotonin reuptake inhibitors. Although no such adverse drug interactions were reported in the clinical trials in dogs, it seems prudent to avoid the combination of Anipryl and selective serotonin reuptake inhibitors (e.g., fluoxetine) as well as Anipryl and tricyclic (e.g., clomipramine, amitriptyline, imipramine) or other antidepressants. At least 14 days should elapse between discontinuation of Anipryl and initiation of treatment with a tricyclic antidepressant or selective serotonin reuptake inhibitor. Because of the long half-life of fluoxetine and its active metabolites, at least 5 weeks should elapse between discontinuation of fluoxetine and initiation of treatment with Anipryl. Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.
Pharmaceutical Precautions Store at controlled room temperature 20°-25°C (68°-77°F). PLEASE NOTE: Anipryl is only available by prescription and REQUIRES A VALID PRESCRIPTION be mailed, faxed or emailed to PetDrugs.com to complete your order. * All final sales are billed in $ USD. All prices are subject to change at any time. For questions regarding pricing and availability of products from PetDrugs.com you may call 1-800-958-1252. |
|||
|
|||
Click to tell a friend about